Newsroom
FarmaMondo Group expands global access to Zemcelpro® through an exclusive partnership with Cordex, an ExCellThera company
FarmaMondo, ExCellThera and Cordex have entered into a commercial partnership to expand access to Zemcelpro® in Singapore, Hong Kong and Argentina, initially through Named Patient Sales. The collaboration aims to address unmet medical needs by providing eligible patients with blood cancers who lack a suitable matched donor access to an innovative stem cell therapy with potentially curative intent.
Published On: July 16, 2026FarmaMondo Group appoints Independent Board Director Natalie Douglas, global pharmaceutical managed access and commercialization pioneer
FarmaMondo Group, an international commercial pharmaceutical organization that partners with pharma and biotech to deliver innovative and specialty medicines to the 50+ emerging markets, today announces the appointment of Natalie Douglas as Independent Board Director.
Published On: May 10, 2026FarmaMondo Group expands reach with the launch of FarmaMondo India PVT. LTD.
FarmaMondo Group is proud to announce the opening of its new office in Mumbai, India- marking their 13th global location across six key regions.
Published On: March 2, 2026FarmaMondo Group and Kedrion Biopharma Announce Exclusive Partnership Agreement for Coagadex® distribution in the Baltics
FarmaMondo Group and Kedrion Biopharma announced an exclusive agreement to distribute Coagadex® (human coagulation factor X) across Estonia, Latvia, and Lithuania.
Published On: October 1, 2025FarmaMondo Group Expands Existing Partnership with Recordati Rare Diseases to Distribute Enjaymo (Sultimlimab-jome)
Farma Mondo Group Expands Existing Partnership with Recordati Rare Diseases, Signing Exclusive Agreement to Distribute Enjaymo (Sultimlimab-jome) in countries where the product is not commercially available.
Published On: September 18, 2025FarmaMondo Group and Pharmazz, Inc. sign exclusive partnership to distribute Tycamzzi™ (Sovateltide) in the Baltic region
Farma Mondo UAB, a subsidiary in Baltics of the FarmaMondo Group, and Pharmazz Inc. (“Pharmazz”) announce the signing of an exclusive partnership for the distribution of Tycamzzi™ in Baltics.
Published On: July 16, 2025FarmaMondo Group and Acadia Pharmaceuticals Inc. entered into an exclusive Distribution Agreement to manage the Supply of DAYBUE® in the emerging markets
Farma Mondo Group and Acadia Pharmaceuticals Inc. have entered into an Exclusive Distribution Agreement to globally manage Named Patient Supply of DAYBUE® (trofinetide).
Published On: May 21, 2025FarmaMondo Group achieved the reimbursement for Carbaglu (Carglumic Acid) in Hong Kong.
FarmaMondo Hong Kong Limited confirms the approval of the reimbursement for Carbaglu (Carglumic Acid) dispersible tablets, on behalf of Recordati Rare Diseases in Hong Kong.
Published On: December 20, 2024GSASA Congress
FarmaMondo at the annual congress of the GSASA (Swiss Association of Hospital Pharmacists)
Published On: November 29, 2024BIO Europe
The BIO Europe conference in Stockholm brings together key players in the biotech scene and therapeutic innovation well beyond Europe. [...]
Published On: November 8, 2024FarmaMondo Group and Recordati UK Ltd. sign exclusive license and distribution agreement for Qarziba® in Hong Kong
Farma Mondo announces the signing with Recordati UK Ltd. (a Recordati Rare Diseases Company) of an exclusive License and Distribution Agreement in Hong Kong for Qarziba® (dinutuximab beta)
Published On: July 15, 2024FarmaMondo Group and HRA Pharma Rare Diseases Sign Exclusive Partnership to Distribute Lysodren (Mitotane) in Brazil
Farma Mondo Group and HRA Pharma Rare Diseases, are pleased to announce the signing of an Exclusive Distribution Agreement for the supply of Lysodren (Mitotane) in Brazil.
Published On: July 4, 2024FarmaMondo Group and Stemline Therapeutics B.V. sign exclusive partnership to grant access to Elacestrant
Farma Mondo Group and Stemline Therapeutics B.V. sign exclusive partnership to grant access to Elacestrant through Named Patient Supplies to patients in certain Countries where the product is not licensed or not commercially available.
Published On: March 1, 2024FarmaMondo Group at Arab Health
FarmaMondo took part in Arab Health 2024 in Dubai at the end of January. Arab Health is the largest gathering [...]
Published On: February 5, 2024FarmaMondo Group @BIO-Europe in Munich
FarmaMondo will be participating in the Bio-Europe Congress in Munich from 6 to 8 November. BIO-Europe® is held annually in [...]
Published On: October 25, 2023FarmaMondo Group signs exclusive partnership to commercialize QRX003 for Netherton Syndrome in Singapore
FarmaMondo Group announces the signing of a licensing and distribution agreement with Quoin Pharmaceuticals Inc. for exclusive rights to commercialize QRX003 in Singapore. The product is currently undergoing clinical development for the treatment of Netherton Syndrome.
Published On: July 28, 2023FarmaMondo Group and Dompé farmaceutici extend their Distribution Partnership for Oxervate®
MILAN, ITALY and CHIASSO, SWITZERLAND, June 1, 2023 – Dompé farmaceutici S.p.A. (“Dompé”) and FarmaMondo Group announced they have extended their agreement whereby FarmaMondo Group becomes Dompé’s distribution partner for Oxervate (cenegermin) in additional selected countries.
Published On: June 1, 2023FarmaMondo Group at BIO Boston 5-8 June 2023
How to bring innovative therapies to patients in growth and emerging markets is a real challenge for medium and small [...]
Published On: April 17, 2023FarmaMondo at EAHP 2023
Come visit us at our booth in the EAHP Congress in Lisbon. From the 22th to the 24th March FarmaMondo [...]
Published On: March 7, 2023FarmaMondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region
FarmaMondo and Helsinn sign an exclusive marketing and distribution agreement in the Baltic region for AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adults.
Published On: November 28, 2022
